PRF Technologies shares are trading higher after the company announced expanded results from its preclinical study directly comparing its lead product candidate, PRF-110, to approved ZYNRELEF.

Benzinga Newsdesk www.benzinga.com Positive 95.5%

Neg 0% Neu 0% Pos 95.5%

Comments

No comments yet. Be the first!